Drug details

Gilotrif (afatinib tablets, for oral use)

type of Antineoplastic Tyrosine Kinase Inhibitors, Antineoplastics EGFR Inhibitors

Gilotrif (afatinib) is a tyrosine kinase inhibitor used to treat non-small cell lung cancer (NSCLC) that has spread (metastasized), whose tumors have a genetic mutation called epidermal growth factor receptor (EGFR).

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• dark urine,
• fever,
• easy bruising,
• unusual bleeding,
• shortness of breath,
• tiredness,
• clay-colored stools,
• yellowing of the skin or eyes (jaundice),
• fluttering in your chest,
• blurred vision,
• trouble swallowing,
• stomach pain (upper right side),
• pounding heartbeats,
• new or worsening cough,
• feeling like something is in your eye,
• red or swollen gums,
• increased sensitivity to light,
• eye pain or redness,
• rapid weight gain
• watery eyes,
• severe or ongoing diarrhea (lasting 2 days or longer),
• severe skin reaction that causes blistering and peeling,
• pain, redness, numbness, and peeling skin on your hands or feet,
• blisters or ulcers in your mouth,
• swelling in your legs and ankles, and

The following drugs are related to Gilotrif, either as a replacement or used together:

• Tabrecta (capmatinib tablets)
• Cosela (trilaciclib for injection)
• Taxotere (docetaxel for injection)
• Tarceva (erlotinib)
• Exkivity (mobocertinib capsules)
• Sancuso (granisetron transdermal system)
• Lorbrena (lorlatinib tablets)